Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration.

Chest - 1 May 1994

Barker A F, Siemsen F, Pasley D, D'Silva R, Buist A S

Abstract excerpt

This retrospective chart review describes the efficacy and safety of long-term administration of intravenous alpha1-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 to 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency
Share to Forced Expiratory Volume

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Infusions, Intravenous

Share to Lung Diseases, Obstructive

Share to Phenotype

Source

Identifiers

PMID: 8181327
DOI: 10.1378/chest.105.5.1406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration.PMID 8181327Read ↗

Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society.Semantic proximity Read ↗

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.Semantic proximity Read ↗

alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.Semantic proximity Read ↗

[Replacement therapy of emphysema caused by alpha 1-antitrypsin deficiency].Semantic proximity Read ↗

Alpha-1 Antitrypsin Augmentation TherapySemantic proximity Read ↗

[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].Semantic proximity Read ↗

[Substitution therapy in alpha 1-antitrypsin deficiency].Semantic proximity Read ↗

Alpha 1-antitrypsin deficiency: pathogenesis and treatment.Semantic proximity Read ↗

Criteria for alpha 1-antitrypsin substitution.Semantic proximity Read ↗

Successful Long-Term Enzyme Replacement Therapy in a Patient with Delayed-Onset ADA Deficiency.Semantic proximity Read ↗

Antiproteinase deficiency, emphysema and replacement therapy.Semantic proximity Read ↗

Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.